Lantheus Medical Imaging has renewed its long-term agreement with FUJIFILM RI Pharma (FRI) to license and distribute its technetium-based radiopharmaceutical imaging agents, used in single-photon emission computed tomography (SPECT), in Japan.
The agent includes Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), which facilitates clinicians for the diagnosis and management of patients with known or suspected coronary artery.
Other agent includes Neurolite (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), which is a SPECT brain imaging agent for localization of stroke in patients in whom stroke has already been diagnosed.
Under the terms of the new 10-year agreement, Lantheus will supply FUJIFILM with Cardiolite and Neurolite in finished form as well as provide the raw materials to manufacture and sell the products in unit dose form.
FUJIFILM RI Pharma president and chief executive officer Yoshiro Kumano said, "Lantheus is the ideal partner for FRI in the Japanese diagnostic imaging market as we have a shared view of the clinical value and benefits of radiopharmaceuticals in the diagnosis of disease."
